scholarly journals 1814MO Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: A randomized, open-label trial

2020 ◽  
Vol 31 ◽  
pp. S1047-S1048
Author(s):  
A. Sharma ◽  
S. Bakhshi ◽  
A. Sharma ◽  
D. Pushpam ◽  
A. Tiwari ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Children And Adolescents ◽  
Myeloid Leukaemia ◽  
Induction Chemotherapy ◽  
Open Label ◽  
Acute Emesis ◽  
Open Label Trial ◽  
Acute Myeloid

Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: a randomised, open-label trial

2020 ◽  
pp. bmjspcare-2020-002595
Author(s):  
Atul Sharma ◽  
Shuvadeep Ganguly ◽  
Santosh Kumar C ◽  
Ashwati S Pillai ◽  
Deepa Dhawan ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Acute Phase ◽  
Induction Therapy ◽  
Control Group ◽  
Open Label ◽  
Link Type ◽  
Open Label Trial ◽  
Delayed Phase ◽  
Acute Myeloid

ObjectivesMore than 50% patients develop emesis during induction therapy for acute myeloid leukaemia (AML). The addition of aprepitant for emesis control in children receiving induction for AML have not been explored.MethodsA single-institutional randomised, open-label trial (NCT02979548) was conducted where children between 5 and 18 years with the diagnosis of AML being planned for 3+7 induction regimen were included. All study participants received ondansetron (0.15 mg/kg) every 8 hours for 8 days starting 30 min prior to chemotherapy. Children belonging to aprepitant group additionally received aprepitant capsules (15–40 kg=days 1–3, 80 mg; >40 kg=day 1, 125 mg and days 2–3, 80 mg) starting from 1 hour prior to chemotherapy. The proportion of patients with complete response (CR) in chemotherapy induced vomiting (CIV) in acute phase (day 1–8), delayed phase (day 9–13), overall and initial 96 hours were recorded along with severity of vomiting and adverse effects.ResultsTotal 78 children were randomised (Aprepitant group: 37 and control group: 41). The proportion of patients with CR in CIV was significantly higher in Aprepitant group in acute phase (p=0.007), overall phase (p=0.007) and in initial 96 hours (p<0.001) but it was not different in delayed phase (p=0.07). The first episode of vomiting was also significantly delayed in aprepitant group (p=0.02). Adverse effect profile was similar in two groups.ConclusionAprepitant significantly improves emesis control in children receiving induction therapy for AML, especially in acute phase and should be routinely incorporated as part of antiemetic prophylaxis.Trial registration numberThe study was registered at ClinicalTrials.gov (NCT02979548).

scholarly journals Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents

2020 ◽  
Vol 136 ◽  
pp. 116-129 ◽  
Author(s):  
Andrew D.J. Pearson ◽  
C.Michel Zwaan ◽  
E.Anders Kolb ◽  
Dominik Karres ◽  
Julie Guillot ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Product Development ◽  
Children And Adolescents ◽  
Myeloid Leukaemia ◽  
Medicinal Product ◽  
Acute Myeloid

Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy

2015 ◽  
Vol 96 (6) ◽  
pp. 586-592 ◽  
Author(s):  
Davide Lazzarotto ◽  
Anna Candoni ◽  
Gianpaolo Nadali ◽  
Laura Pavan ◽  
Federica Lessi ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Chemotherapy ◽  
Failed Induction ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document